Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1Breast 1

Conditions

Squamous Non-Small Cell Lung Cancer 1Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 297Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × lumretuzumab × Clear all
NCT01918254 2017-09-12

A Study to Evaluate Lumretuzumab in Combination With Pertuzumab and Paclitaxel in Participants With Metastatic Breast Cancer Expressing Human Epidermal Growth Factor Receptor (HER) 3 and HER2 Protein

Hoffmann-La Roche

Phase 1 Completed
66 enrolled
Breast

Breast Neoplasms

NCT01482377 2017-01-27

A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell Origin

Hoffmann-La Roche

Phase 1 Completed
145 enrolled
Tumor-Agnostic

Neoplasms

NCT02204345 2017-01-25

A Study Evaluating RO5479599 in Combination With Carboplatin and Paclitaxel in Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) of Squamous Histology

Hoffmann-La Roche

Phase 1/2 Terminated
12 enrolled
Thoracic

Squamous Non-Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡